Ranbaxy Pharmaceuticals Inc. is voluntarily recalling select batches and dosages of atorvastatin calcium tablets, a generic version of the cholesterol-lowering drug Lipitor, in the United States.


Ranbaxy Pharmaceuticals, atorvastatin calcium tablets, recall, United States, U.S. market, generic version, Lipitor


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Ranbaxy recalls generic Lipitor in U.S.

November 23rd, 2012

PRINCETON, N.J. – Ranbaxy Pharmaceuticals Inc. is voluntarily recalling select batches and dosages of atorvastatin calcium tablets, a generic version of the cholesterol-lowering drug Lipitor, in the United States.

The drugmaker said on its website Friday that the recall is being conducted in the U.S. market at the retail level because some batches may contain small glass particles less than 1 mm in size.

Ranbaxy reported that the recall involves certain lot numbers of atorvastatin in strengths of 10 mg, 20 mg and 40 mg, packaged in 90-count and 500-count bottles.

The company noted that the recall doesn't involve the 80-mg atorvastatin or any other Ranbaxy product.

"Ranbaxy is proactively recalling the drug product lots out of an abundance of caution and in keeping the safety of our customers in mind," the company stated. "This recall is being conducted with the full knowledge of the U.S. FDA. The recall is limited to the U.S. market only and affects specific lots numbers and strengths of this molecule manufactured by Ranbaxy only for sale in the U.S."

Advertisement